HIV/HBV合并感染患者抗病毒治疗的效果及与病毒载量之间相关性分析

Abstract
Figure/Table
References (20)
Related Citation (13)

Download: PDF (624 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the effect of antiviral therapy and correlation with viral load in patients with human immuncodeficiency virus/hepatits B virus (HIV/HBV) co-infection. Methods From January 2017 to December 2018, 147 patients with HBV and HIV infection in the Department of Infectious Diseases of the Third People′s Hospital of Guilin, Guangxi Zhuang Autonomous Region were selected as the research subjects. According to the type of infection, the patients were divided into three groups: 49 cases in HBV group, 50 cases in HIV group, and 48 cases in HIV/HBV group. Prospective analysis was conducted to calculate the correlation between liver and kidney function indexes of three groups of patients before and after treatment with HIV ribonucleic acid (HIV-RNA) and HBV deoxyribonucleic acid (HBV-DNA). Results The levels of alanine aminotransferase (ALT), total bilirubin (TBil) and direct bilirubin (DBil) in the HBV group after 24 weeks of treatment were lower than those after 12 weeks, and the levels of ALT, TBil and DBil after 48 weeks of treatment were lower than those after 24 weeks of treatment, and the differences were statistically significant (all P ＜ 0.05). The levels of TBil and DBil in the HIV group after 12 and 24 weeks of treatment were higher than those before treatment, aspartate aminotrransferase (AST) levels after 24 weeks of treatment were lower than those before treatment, after 48 weeks of treatment, the levels of AST, TBil and DBil were lower than those after 24 weeks of treatment, and the differences were statistically significant (P ＜ 0.05). After 12 weeks of treatment, the DBil level in the HIV/HBV group was lower than that before treatment, after 24 weeks of treatment DBil level was lower than that after 12 weeks of treatment, and that after 48 weeks of treatment was lower than that after 24 weeks of treatment, and the differences were statistically significant (P ＜ 0.05). After 24 weeks of treatment, the HBV-DNA level of the HIV/HBV group was higher than that of the HBV group, and the difference was statistically significant (P ＜ 0.05). After 24 weeks and 48 weeks of treatment, the levels of HIV-RNA in the HIV/HBV group were higher than that in the HIV group, and the differences were statistically significant (P ＜ 0.05). Conclusion The antiviral therapy is effective in the recovery of liver function for those HIV/HBV co-infected, but it is still difficult to eliminate HIV and HBV.

Key words： Human immunodeficiency virus Hepatitis B virus Antiviral therapy Liver and kidney function

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	HUANG Chengjun1 CHENG Shuquan1▲ TIAN Qun1 LIN Jun2

Cite this article:

HUANG Chengjun1 CHENG Shuquan1▲ TIAN Qun1 LIN Jun2. Analysis on the effect of antiviral therapy and correlation with viral load in patients with HIV/HBV co-infection[J]. 中国医药导报, 2020, 17(28): 28-31.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2020/V17/I28/28

[1] 崔富强，庄辉.中国乙型肝炎的流行及控制进展[J].中国病毒病杂志，2018，12（4）：257-264.
[2] 徐葵花.乙型肝炎病毒基因型的临床研究进展[J].实用肝脏病杂志，2016，7（1）：59-61.
[3] 张冬琴，张海月，吴吉圆，等.恩替卡韦与拉米夫定治疗HBV相关性肝衰竭患者疗效Meta分析[J].实用肝脏病杂志，2014，6：606-610.
[4] 徐静，鲍磊，王玉，等.替比夫定联合阿德福韦酯与拉米夫定联合阿德福韦酯治疗慢性乙型肝炎对肾功能影响的对比研究[J].中华肝脏病杂志，2018，26（4）：288-293.
[5] 赖玺杰，连江山，陈涧阳，等.拉米夫定和阿德福韦酯初始联合治疗慢性乙型肝炎和乙型肝炎肝硬化患者替换为恩替卡韦单药治疗的疗效和安全性观察[J].中华肝脏病杂志，2018，26（2）：113-118.
[6] 宋爱心，代丽丽.HIV合并HBV感染研究进展[J].中国艾滋病性病，2018，24（10）：1062-1065.
[7] 李伟华，李传云，闫惠平，等.HIV急性期/早期感染者合并HBV感染的临床特征[J].中国艾滋病性病，2014，20（4）：233-236.
[8] 黄丹，王彦，张福杰.北京地区HIV/HBV合并感染者与HBV单独感染者中HBV基因型分布[J].中国艾滋病性病，2019，3（4）：227-230.
[9] Krastev Z，Petrova D，Kotzev I，et al. Telbivudine vs tenofovir in hepatitis B e antigen-negative chronic hepatitis B patients：OPTIMA roadmap study [J]. World J Hepatol，2016，8（32）：1402-1413.
[10] 刘秀丽，陈润柱，徐风.恩替卡韦治疗高病毒量HBV感染并肺结核肝损害的临床效果研究[J].北方药学，2019， 7：44-45.
[11] 雷鹏.美沙酮联合抗病毒治疗HIV感染的临床效果观察[J].临床合理用药杂志，2016，9（8）：49-50.
[12] 聂源，廖宝林，胡凤玉，等.HIV/HBV合并感染者HBV Pre-S/S区抗原表位变异分析[J].中华实验和临床病毒学杂志，2019，33（2）：131-135.
[13] 陈柳林，黄树庭.含洛匹那韦/利托那韦的初治抗病毒方案治疗HIV/HCV合并感染者的疗效观察[J].中国艾滋病性病，2014，20（12）：895-897.
[14] 饶和平，靳昌忠，金祥宁，等.不同HAART方案对HIV合并HCV感染患儿肝功能和HIV载量的影响[J].重庆医学，2017，46（15）：2045-2047.
[15] 陈昭云，李自钊，赵清霞，等.HIV合并HBV感染的患者抗病毒治疗效果分析[J].中国艾滋病性病，2016，22（10）：776-778.
[16] 彭忠秀，李晶，汤恋花，等.HIV合并HBV感染对患者免疫功能和肝功能的影响[J].深圳中西医结合杂志，2016， 16：3-5.
[17] 冯丹，姚添，程雁鹏，等.艾滋病病毒感染者合并乙型肝炎病毒感染现状及其相关因素研究[J].中华流行病学杂志，2017，38（12）：1624-1628.
[18] 陈仁芳，郑毓芳，徐淑凡，等.基于替诺福韦和拉米夫定初始联合的高效抗反转录病毒治疗艾滋病合并乙型肝炎病毒感染72周的疗效[J].中华临床感染病杂志，2016，6（3）：153-156.
[19] Saha D，Pal A，Sarkar N，et al. Occult hepatitis B virus infection in HIV positive patients at a tertiary healthcare unit in eastern India [J]. PloS One，2017，12（6）：e0179035.
[20] 李伟华，闫惠平，李传云，等.艾滋病病毒/乙型肝炎病毒重叠感染对肝脏损伤的比较分析[J].中华流行病学杂志，2008，29（3）：306-307.